Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. (October 2008)

• Record Type: Journal Article
• Authors: Ikeda, Masashi; Yamanouchi, Yoshio; Kinoshita, Yoko; Kitajima, Tsuyoshi; Yoshimura, Reiji; Hashimoto, Shuji; O''Donovan, Michael C; Nakamura, Jun; Ozaki, Norio; Iwata, Nakao
• Is Part Of: Pharmacogenomics. Volume 9:Number 10(2008)
• Page Start: 1437
• Page End: 1443
• Publication Date: 2008-10
• Subjects: dopamine -- pharmacogenetics -- risperidone -- schizophrenia -- serotonin; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/14622416.9.10.1437
• Languages: English
• ISSNs: 1462-2416

Abstract

Aims: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes ( DRD1––DRD5, AKT1 and GSK3 ββ) and serotonin receptor genes ( HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7 ) can be used to predict the efficacy of risperidone treatment for schizophrenia.Materials & methods: A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale.Results: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone.Conclusion: These data suggest that the SNPs in DRD2 and AKT1 may influence the treatment response to risperidone in schizophrenia patients.